Timing of Tocilizumab Administration Under the Guidance of IL-6 in CAR-T Therapy for R/R Acute Lymphoblastic Leukemia

Chimeric antigen receptor T (CAR-T) cells targeting CD19 have achieved great clinical responses in patients with relapsed or refractory (R/R) acute B lymphoblastic leukemia. However, severe adverse events such as cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndr...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Yinqiang Zhang, Fen Zhou, Zhuolin Wu, Yingnan Li, Chenggong Li, Mengyi Du, Wenjing Luo, Haiming Kou, Cong Lu, Heng Mei
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Frontiers Media S.A. 2022-06-01
coleção:	Frontiers in Immunology
Assuntos:	chimeric antigen receptor T cell cytokine release syndrome acute lymphoblastic leukemia tocilizumab interleukin-6
Acesso em linha:	https://www.frontiersin.org/articles/10.3389/fimmu.2022.914959/full
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!